Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313784156> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W4313784156 endingPage "42" @default.
- W4313784156 startingPage "32" @default.
- W4313784156 abstract "Introduction . The tactics of managing and treating patients with chronic recurrent bacterial prostatitis (CRBP) in some cases is a difficult-to-treat condition for a practicing urologist. This circumstance occurs because the disease has several predisposing factors, a complex and multifaceted pathogenesis, and certain difficulties in diagnosis and treatment. Objective . To study the effectiveness of recombinant interferon α-2b medications in post-COVID-19 patients with chronic recurrent prostatitis against the background of antibiotic multi-drug resistance of microorganisms verified in prostate secretion. Materials and methods . The treatment of 52 post-COVID-19 patients with CRBP was analyzed, divided into three therapy-dependent groups. Group 1 patients (n = 18) received antibiotic therapy (ABT): Levofloxacin 500 mg q.d. PO for 28 days. Group 2 patients (n = 18) underwent combined therapy: ABT supplemented with recombinant interferon α-2b with an antioxidant complex of vitamins E and C (“Viferon®” rectal suppositories) 3.000.000 IU b.i.d. PR q12h for 28 days. Group 3 patients (n = 16) received monotherapy with recombinant interferon α-2b with an antioxidant complex of vitamins E and C (“Viferon®”rectal suppositories) 3.000.000 IU b.i.d. PR q12h for 28 days. The follow-up period was 6 months with monitoring of clinical and laboratory parameters assessed before treatment, after 1, 3 and 6 months from the start of therapy. Results . Based on the monitoring of the clinical picture and laboratory parameters, after 1 follow-up month, there was a significant decrease in the symptoms of the disease in all study groups. However, after 3 and 6 follow-up months, this trend was observed only in patients of groups 2 and 3 receiving recombinant interferon alfa-2b with an antioxidant complex (vitamins E and C). Conclusions . Strengthening the standard CRBP-therapy with recombinant interferon α-2b with an antioxidant complex of vitamins E and C makes it possible to normalize both clinical and laboratory parameters in most patients." @default.
- W4313784156 created "2023-01-08" @default.
- W4313784156 creator A5036360293 @default.
- W4313784156 creator A5048233462 @default.
- W4313784156 creator A5049012305 @default.
- W4313784156 creator A5050902986 @default.
- W4313784156 creator A5051828170 @default.
- W4313784156 creator A5065712143 @default.
- W4313784156 creator A5087683818 @default.
- W4313784156 date "2022-12-26" @default.
- W4313784156 modified "2023-09-29" @default.
- W4313784156 title "Treatment of post-COVID-19 patients with chronic recurrent prostatitis: efficacy of recombinant interferon α-2b medications" @default.
- W4313784156 cites W2586728690 @default.
- W4313784156 cites W2754237085 @default.
- W4313784156 cites W2795606355 @default.
- W4313784156 cites W2947246378 @default.
- W4313784156 cites W3022448896 @default.
- W4313784156 cites W3084119495 @default.
- W4313784156 cites W3138934758 @default.
- W4313784156 cites W3159429104 @default.
- W4313784156 cites W3198712501 @default.
- W4313784156 cites W3214660250 @default.
- W4313784156 cites W4285734563 @default.
- W4313784156 doi "https://doi.org/10.21886/2308-6424-2022-10-4-32-42" @default.
- W4313784156 hasPublicationYear "2022" @default.
- W4313784156 type Work @default.
- W4313784156 citedByCount "0" @default.
- W4313784156 crossrefType "journal-article" @default.
- W4313784156 hasAuthorship W4313784156A5036360293 @default.
- W4313784156 hasAuthorship W4313784156A5048233462 @default.
- W4313784156 hasAuthorship W4313784156A5049012305 @default.
- W4313784156 hasAuthorship W4313784156A5050902986 @default.
- W4313784156 hasAuthorship W4313784156A5051828170 @default.
- W4313784156 hasAuthorship W4313784156A5065712143 @default.
- W4313784156 hasAuthorship W4313784156A5087683818 @default.
- W4313784156 hasBestOaLocation W43137841561 @default.
- W4313784156 hasConcept C104317684 @default.
- W4313784156 hasConcept C121608353 @default.
- W4313784156 hasConcept C126322002 @default.
- W4313784156 hasConcept C185592680 @default.
- W4313784156 hasConcept C203014093 @default.
- W4313784156 hasConcept C2776178377 @default.
- W4313784156 hasConcept C2776235491 @default.
- W4313784156 hasConcept C2780524745 @default.
- W4313784156 hasConcept C2781276175 @default.
- W4313784156 hasConcept C40767141 @default.
- W4313784156 hasConcept C501593827 @default.
- W4313784156 hasConcept C55493867 @default.
- W4313784156 hasConcept C71924100 @default.
- W4313784156 hasConcept C86803240 @default.
- W4313784156 hasConcept C89423630 @default.
- W4313784156 hasConcept C90924648 @default.
- W4313784156 hasConceptScore W4313784156C104317684 @default.
- W4313784156 hasConceptScore W4313784156C121608353 @default.
- W4313784156 hasConceptScore W4313784156C126322002 @default.
- W4313784156 hasConceptScore W4313784156C185592680 @default.
- W4313784156 hasConceptScore W4313784156C203014093 @default.
- W4313784156 hasConceptScore W4313784156C2776178377 @default.
- W4313784156 hasConceptScore W4313784156C2776235491 @default.
- W4313784156 hasConceptScore W4313784156C2780524745 @default.
- W4313784156 hasConceptScore W4313784156C2781276175 @default.
- W4313784156 hasConceptScore W4313784156C40767141 @default.
- W4313784156 hasConceptScore W4313784156C501593827 @default.
- W4313784156 hasConceptScore W4313784156C55493867 @default.
- W4313784156 hasConceptScore W4313784156C71924100 @default.
- W4313784156 hasConceptScore W4313784156C86803240 @default.
- W4313784156 hasConceptScore W4313784156C89423630 @default.
- W4313784156 hasConceptScore W4313784156C90924648 @default.
- W4313784156 hasIssue "4" @default.
- W4313784156 hasLocation W43137841561 @default.
- W4313784156 hasOpenAccess W4313784156 @default.
- W4313784156 hasPrimaryLocation W43137841561 @default.
- W4313784156 hasRelatedWork W2157483319 @default.
- W4313784156 hasRelatedWork W2348975012 @default.
- W4313784156 hasRelatedWork W2350327883 @default.
- W4313784156 hasRelatedWork W2353236179 @default.
- W4313784156 hasRelatedWork W2375695784 @default.
- W4313784156 hasRelatedWork W2389302311 @default.
- W4313784156 hasRelatedWork W2406166845 @default.
- W4313784156 hasRelatedWork W3031054259 @default.
- W4313784156 hasRelatedWork W4287622944 @default.
- W4313784156 hasRelatedWork W4206859193 @default.
- W4313784156 hasVolume "10" @default.
- W4313784156 isParatext "false" @default.
- W4313784156 isRetracted "false" @default.
- W4313784156 workType "article" @default.